1 / 30

‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial

‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial. Philip Bath, ENOS Chief Investigator Sri Lanka 15 March 2010. www.enos.ac.uk/. Welcome. To: Existing, New, or Potential sites. Efficacy of Nitric Oxide in Stroke (ENOS). Does lowering blood pressure improve outcome?

ramona-chapman
Télécharger la présentation

‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial Philip Bath, ENOS Chief Investigator Sri Lanka 15 March 2010 www.enos.ac.uk/

  2. Welcome To: Existing, New, or Potential sites

  3. Efficacy of Nitric Oxide in Stroke (ENOS) • Does lowering blood pressure improve outcome? • Interventions (for 7 days): • Transdermal glyceryl trinitrate (5 mg daily) or control • Continue / stop prior antihypertensive therapy (in those on antihypertensives prior to stroke) • Ischaemic or haemorrhagic stroke within 48 hours • 5,000 patients • Internet: Randomisation, data collection, trial management • 1,719 patients, 128 centres, 16 countries, 5 continents (03/10) • New centres very welcome! • Funding: Hypertension Trust, BUPA Foundation, MRC ENOS Trial Investigators. Int J Stroke 2006;1:245-9 www.enos.ac.uk/

  4. ENOS: Aims / interventions Does acute lowering of BP with GTN reduce death and dependency? • GTN 5mg daily for 7 days or nothing Should prior antihypertensive medication be continued or temporarily stopped during the acute phase of stroke? • Stop/continue prior treatment for 7 days On top of standard evidence-based acute medical and nursing care, and secondary prevention www.enos.ac.uk/

  5. ENOS: Interventions • No prior antihypertensive therapy (~50%) • GTN • No GTN • Prior antihypertensive therapy (~50%) • GTN / stop • GTN / continue • No GTN / stop • No GTN / continue www.enos.ac.uk/

  6. ENOS: Inclusion criteria • Adult (age > 18 years) • Clinical stroke syndrome with limb weakness lasting >1 hour • So not likely to be a transient ischaemic attack • Residual limb weakness at the time of enrolment • Onset < 48 hours. If the time of onset is unknown, apply the time when the patient was last known to be well • Conscious (Glasgow Coma Scale > 8) • Systolic blood pressure 140-220 mmHg inclusive • In at least one of the three pre-randomisation measures • Independent prior to stroke • Pre-morbid modified Rankin Scale < 2 • Meaningful consent • Or proxy consent from a relative or carer, or proxy consent from an independent physician if patient unable to give meaningful consent • E.g. If dysphasia, confusion, or reduced conscious level www.enos.ac.uk/

  7. ENOS: Exclusion criteria • Need for nitrate • Myocardial infarction, unstable angina, heart failure • Contraindication to nitrate • Dehydration/hypovolaemia, HOCM, sildenafil • Need for prior antihypertensive therapy • Definite need for new antihypertensive • New antihypertensive commenced post stroke • Expected to need for surgery • Known intracranial pathology other than stroke • Pregnant females • Not available for follow-up www.enos.ac.uk/

  8. ENOS: Status Start up commenced 4 July 2001 MRC grant commenced 1 Nov 2006 To date 14 March 2010 Patients 1,719 Continue-stop 840 (49%) Centres - ever recruited 90 Countries 16 Continents 5 Sri Lanka 50 2 centres www.enos.ac.uk/

  9. ENOS: Baseline GTN/none Continue/stop Subjects 1686 821 (49%) Age (mean) 70 72 Male (%) 58 52 Recent nitrate (%) 5 9 Prior high BP (%) 65 95 SBP (mmHg) 168 168 AF (%) 12 18 Severity (SSS) 34 34 Time < 24h (%) 34 33 www.enos.ac.uk/ As at 22/02/2010

  10. ENOS: Baseline, All patients RoW Sri Lanka Subjects 1636 50 Age (mean) 70 62 Male (%) 57 74 Recent nitrate (%) 5 2 Prior high BP (%) 65 50 SBP (mmHg) 168 171 AF (%) 13 0 Severity (SSS) 34 38 Time < 24h (%) 34 32 www.enos.ac.uk/ As at 23/02/2010

  11. ENOS: Baseline, All patients RoW India Subjects 1626 60 Age (mean) 70 59 Male (%) 58 65 Recent nitrate (%) 5 2 Prior high BP (%) 65 65 SBP (mmHg) 168 175 AF (%) 13 2 Severity (SSS) 35 30 Time < 24h (%) 34 43 www.enos.ac.uk/ As at 23/02/2010

  12. ENOS: Baseline, Continue/stop RoW Sri Lanka Subjects 808 (49%) 13 (26%) Age (mean) 73 59 Male (%) 52 77 Recent nitrate (%) 9 8 Prior high BP (%) 95 100 SBP (mmHg) 168 174 AF (%) 19 0 Severity (SSS) 34 37 Time < 24h (%) 33 54 www.enos.ac.uk/ As at 23/02/2010

  13. ENOS: Baseline, Continue/stop RoW India Subjects 821 (50%) 17 (28%) Age (mean) 72 65 Male (%) 53 41 Recent nitrate (%) 9 0 Prior high BP (%) 95 88 SBP (mmHg) 168 173 AF (%) 18 6 Severity (SSS) 34 33 Time < 24h (%) 34 53 www.enos.ac.uk/ As at 23/02/2010

  14. ENOS: Time Recruitment is often late: • Most patients recruited >24 hours • <12 hours 11% • <24 hours 34% ENOS needs: • Early patients if it is to answer the question of how to manage hyperacute BP

  15. ENOS: Stroke type Non-adjudicated information from investigator www.enos.ac.uk/ As at 11/2/2008, n=854

  16. ENOS: Outcomes, day 7 % GTN Stop/continue Death 2.3 1.0 Recurrence 2.5 3.3 Infarction 1.8 2.5 Haemorrhage 0.4 0.4 Unknown 0.4 0.5 Deterioration 8.0 6.8 Worsening of SSS (>4) 7.5 6.6 SNSS (/58) 44 45 (at baseline 38 38) www.enos.ac.uk/ N=845/394

  17. ENOS: Rankin, day 90 Planned mRS >2 = 48% Current mRS >2 = 55% Current mRS >2 = 58% www.enos.ac.uk/ N=1,686 / 821

  18. ENOS: SAEs Total SAE 557 Adjudicated 479 Confirmed 475 Not SAE 4 SUSAR 0 As at 23/02/2010

  19. SAE (n): Total 178 SUSAR 0 During treatment 80 Relationship to treatment ‘Definite’ 1 ‘Probable’ 1 ‘Possible’ 22 Category (%): Cardiovascular 30 CNS 71 Extension 17 Recurrence 15 GI 8 GU 10 Respiratory 36 Miscellaneous 26 ENOS: SAEs

  20. ENOS: Data MonitoringCommittee Members: Professor Peter Sandercock Chair, Neurologist Professor Kjell Asplund Stroke Physician Dr Colin Baigent Epidemiologist Ms Laura Gray, Dr Paul Silcocks Statistician Date N Comment Dec 2002 67 Continue May 2003 113 Continue, data quality ++ Nov 2003 174 Continue Nov 2004 282 Continue, data quality ++ Nov 2005 380 Continue April 2006 463 Continue, congratulations MRC Dec 2006 520 Continue May 2007 658 Continue Dec 2007 795 Continue, data quality ++ May 2008 1000 Continue Dec 2008 1065 Commend investigators for data May 2009 1231 No concerns Nov 2009 1550 Continue without modification www.enos.ac.uk/

  21. Canada Eire UK Italy Poland (Georgia) China/ Hong Kong Philippines (USA) Spain Romania (Saudi Arabia) India Malaysia Singapore New Zealand Egypt Sri Lanka Australia

  22. Expansion New country: Saudi Arabia Potential new countries: SCAST Belgium Denmark Norway Sweden

  23. Recruitment • Startup phase • Main phase

  24. Centres and recruitment Ever recruited 90 UK 61 Overseas 29 Active within last 90 days 43 Not recruited in last 90 days 46 UK 30 (49%) Overseas 16 (55%) Recruited in last 90 days: • 16 centres have rate: 1.3 to 4.0 pat/month • 1 x 12, 3 x 7, 3 x 6, 2 x 5, 7 x 4

  25. ENOS: Data quality • OCSP/Bamford • Need to record hemianopia, inattention, brain stem • Stroke type • Hospital event: ischaemic, haemorrhagic, or unknown • CT scan: different • TOAST • Not entered, no carotid doppler data

  26. Pre-stroke hypertension • ~50% patients on antihypertensive medication • Continue • Lower blood pressure with potential benefits/hazards? • ‘Beneficial’ drug classes: ACE-I, ARA, NO ? • ‘Detrimental/neutral’ drug classes: CCBs, ß-RA ? • Effects on cerebral blood flow • Administration in presence of dysphagia • Prior non-compliance -> massive fall in BP • Stop temporarily • Rise in BP? No • (Remember to re-start for secondary prevention)

  27. COSSACS • Continue vs. stop temporarily • Ischaemic or haemorrhage, <48 hours • Primary: Death or dependency at 2 weeks • UK only • N=763 (ENOS currently 758) • But somewhat different patients • Results to be presented ESC May 2010 • Implications for ENOS? • Please keep recruiting into ENOS – we will update • Prospective individual patient meta-analysis

  28. MRC Extension to trial • Request to extend by 2 years • End October 2011 to end October 2013 • Intention to recruit at least 3,500+ patients • Ideally >3,500 up to 5,000 • Sample size 5,000 to 3,500+ • Use ordinal ‘shift’, not binary, analysis of mRS • Adjust baseline for covariates • Maintain statistical power at 90% • 80% for binary analysis • If positive, ordinal NNT for GTN 10 (at £6 pp)

  29. ENOS: Staff www.enos.ac.uk/

  30. Thanks. Any questions? We hope you will join/continue with the trial

More Related